Contineum Therapeutics, Inc.
Contineum Therapeutics (CTNM) and Johnson & Johnson (JNJ) reported that their depression drug, JNJ-5120/PIPE-307, failed to meet the primary endpoint in a Phase 2 trial. The drug showed no new safety issues but did not demonstrate the required efficacy in treating major depressive disorder. JNJ is analyzing additional data to determine the next steps for the program.
Goldman Sachs initiated coverage on Contineum Therapeutics (NASDAQ:CTNM) with an Early-Stage Biotech rating. The stock trades at $12.51, down 5.3% in a week. The company is developing oral therapies for inflammatory and fibrotic conditions. Its lead candidate, PIPE-791, is in a Phase 2 trial for idiopathic pulmonary fibrosis. Despite a recent trial failure, Stifel maintains a Buy rating with a $28 price target.
RBC Capital's Brian Abrahams maintained a Buy rating and $21.00 price target for Contineum Therapeutics (CTNM). The analyst has a 12.1% average return and 51.90% success rate. The Street's consensus is Strong Buy with a $22.14 average target. CTNM reported a $15.15M quarterly net loss, improving from last year's $16.04M.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning CTNM (Contineum Therapeutics, Inc.). Coverage has skewed bearish: 0 bullish, 1 neutral, and 2 bearish.
Recent CTNM coverage spans technology, earnings and insider activity.
In the last 30 days, CTNM insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($41K). The most active reporter was Stengone Carmine N., CEO and President, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Negative trial data likely pressures CTNM stock lower.
Analyst initiation and trial outcome may pressure the stock lower in the short term.
Analyst reaffirmation may provide modest support but adds little new information.
Negative trial data likely triggers short‑term sell pressure and may pressure valuation until next pipeline readout.
Negative trial data likely pressures the stock lower in the short term.
AlphAI scores every news story that mentions CTNM with an AI model for sentiment and relevance, and aggregates insider trades from Contineum Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Contineum Therapeutics (CTNM) and Johnson & Johnson (JNJ) reported that their depression drug, JNJ-5120/PIPE-307, failed to meet the primary endpoint in a Phase 2 trial. The drug showed no new safety issues but did not demonstrate the required efficacy in treating major depressive disorder. JNJ is analyzing additional data to determine the next steps for the program.
4 min readGoldman Sachs initiated coverage on Contineum Therapeutics (NASDAQ:CTNM) with an Early-Stage Biotech rating. The stock trades at $12.51, down 5.3% in a week. The company is developing oral therapies for inflammatory and fibrotic conditions. Its lead candidate, PIPE-791, is in a Phase 2 trial for idiopathic pulmonary fibrosis. Despite a recent trial failure, Stifel maintains a Buy rating with a $28 price target.
2 min readRBC Capital's Brian Abrahams maintained a Buy rating and $21.00 price target for Contineum Therapeutics (CTNM). The analyst has a 12.1% average return and 51.90% success rate. The Street's consensus is Strong Buy with a $22.14 average target. CTNM reported a $15.15M quarterly net loss, improving from last year's $16.04M.
1 min readContineum Therapeutics (CTNM) shares fell 10% after-hours after J&J's (JNJ) mid-stage trial of PIPE-307, licensed from CTNM, failed to meet its primary goal in treating major depressive disorder. This is the second mid-stage setback for the molecule in under a year. JNJ is reviewing exploratory measures and has not decided on further development. CTNM has $236.6 million in cash, expected to last through mid-2029.
2 min readContineum Therapeutics (CTNM) shares dropped 8% after reporting its phase 2 trial for JNJ-5120/PIPE-307 in major depressive disorder failed to meet its primary endpoint. The drug was well-tolerated, and Johnson & Johnson is reviewing the data to determine next steps. Contineum Therapeutics is a clinical-stage biopharmaceutical company.
1 min readContineum Therapeutics (CTNM) shares rose from lows to a 52-week high. The company's lead drug, PIPE-791, is in a Phase 2 trial for idiopathic pulmonary fibrosis. CTNM's stock has climbed 125% since February 2025, with key catalysts including positive trial results and upcoming conferences. The company also collaborates with Johnson & Johnson on PIPE-307 for depression.
2 min readContineum Therapeutics, Inc. (CTNM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CONTINEUM THERAPEUTICS REPORTS SECOND-QUARTER 2026 FINANCIAL RESULTS; AFFIRMS KEY CLINICAL DEVELOPMENT MILESTONES SAN DIEGO – July 30, 2026 – Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering
6 min readLorrain Daniel S. (Chief Scientific Officer) sold 37,179 shares of Contineum Therapeutics, Inc. (CTNM) at an average of $15.99 ($15.67–$16.24, $0.59M total) across 3 trades over 2026-06-30 to 2026-07-01 under a Rule 10b5-1 trading plan.
2 min readContineum Therapeutics, Inc. (CTNM) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. ctnm-20260626 0001855175 FALSE 0001855175 2026-03-05 2026-03-05 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________________ FORM 8-K ________________________________________________________________
2 min readLorrain Daniel S. (Chief Scientific Officer) sold 4,170 shares of Contineum Therapeutics, Inc. (CTNM) at $13.16 on 2026-06-01 under a Rule 10b5-1 trading plan.
2 min read
